Responding to Diseases in Real-time

Full Event: https://biturl.top/3eMVNb

Session Insights: TBA

As the world struggles to deal with disruptions brought about by a major pandemic, the race to finding a cure for COVID-19 is in full swing across the globe.  This race has dominated by the largest, most well-resourced pharmaceuticals and labs, with the exception of a few smaller, more nimble start-ups that have bucked this trend. Earlier in June, Tychan Pte Ltd became the first in Singapore to kick off human clinical trials for a COVID-19 monoclonal antibody, taking only 4 months to do so - achieving all this without the same resources or capital of a large pharmaceutical!  Together with A*StartCentral, we're exceptionally pleased to have in conversation Prof. Eng Eong Ooi, Founder of Tychan and Professor at Duke-NUS Medical School as we hear how Tychan responds to diseases in real-time, and what enables them to overcome the odds.